Next, we sought to validate our findings in one additional basal-like breast cancer cell line, BT-549, and investigated whether LDHC silencing differentially affects gene expression in other breast cancer subtypes through a comparative analysis of the Her2-enriched HCC-1954 cell line. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.